MAPT and Alzheimer disease: Moreover, plasma p-tau levels correlated with both tau- and Aβ-pathology burdens detected by positron emission tomography (PET) [8] or by CSF Aβ42 [9] in dementia with Lewy bodies (DLB), supporting the clinical use of plasma p-tau as a marker of AD co-pathology.